Details

Autor(en) / Beteiligte

• Yasumoto, Akihiro
• Fujimori, Haruna
• Mochizuki, Mai
• Shibuya-Takahashi, Rie
• Nakamura-Shima, Mao
• Shindo, Norihisa
• Yamaguchi, Kazunori
• Fukushi, Daisuke
• Wakui, Yuta
• Sugai, Takahiro
• Iwai, Wataru
• Abue, Makoto
• Sato, Ikuro
• Satoh, Kennichi
• Katayose, Yu
• Yasuda, Jun
• Shibata, Chikashi
• Tamai, Keiichi

Titel

BEX2 is poor prognostic factor and required for cancer stemness in gastric cancer

Ist Teil von

• Biochemical and biophysical research communications, 2023-05, Vol.655, p.59-67

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Gastric cancer is the fifth most common malignancy worldwide. However, targeted therapy for advanced gastric cancer is still limited. Here, we report BEX2 (Brain expressed X-linked 2) as a poor prognostic factor in two gastric cancer cohorts. BEX2 expression was increased in spheroid cells, and its knockdown decreased aldefluor activity and cisplatin resistance. BEX2 was found to upregulate CHRNB2 (Cholinergic Receptor Nicotinic Beta 2 Subunit) expression, a cancer stemness-related gene, in a transcriptional manner, and the knockdown of which also decreases aldefluor activity. Collectively, these data are suggestive of the role of BEX2 in the malignant process of gastric cancer, and as a promising therapeutic target. •BEX2 (Brain expressed X-linked 2) is a new prognostic marker for gastric cancer.•BEX2 enhances cancer stem cell-related phenotypes.•BEX2 increases CHRNB2 transcript, a cancer stem cell-related gene.